Notably, the treatment-resistant CHC subset exhibits an enrichment of cells with upregulated CK expression and downregulated CD45 expression across the patient cohort, perhaps representing a distinct cellular identity with more tumor-like characteristics and diminished immune features. Here, PTPRC is linked to neoplasm.